Статья
Применение ривароксабана для профилактики инсульта при неклапанной фибрилляции предсердий у больных пожилого и старческого возраста
В обзоре представлены данные об эффективности и безопасности прямого перорального антикоагулянта ривароксабана в профилактике инсульта у пожилых полиморбидных больных с неклапанной фибрилляцией предсердий. В этом аспекте анализируются результаты рандомизированного контролируемого исследования ROCKET-AF по прямому сопоставлению ривароксабана и варфарина у больных с неклапанной фибрилляцией предсердий. Рассматриваются результаты применения ривароксабана у больных пожилого и старческого возраста в повседневной врачебной практике.
1. Boriani G, Diemberger I, Martignani C, Biffi M, Branzi A. The epi- demiological burden of atrial fibrillation: a challenge for clinicians and health care systemsThe opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology. European Heart Journal. 2006;27(8):893–4. DOI:10.1093/eurheartj/ehi651
2. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal. 2016;37(38):2893–962. DOI:10.1093/eurheartj/ehw210
3. January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleve- land JC et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients with Atrial Fibrillation. Journal of the American College of Cardiology. 2019;74(1):104–32. DOI:10.1016/j.jacc.2019.01.011
4. Perera V, Bajorek BV, Matthews S, Hilmer SN. The impact of frailty on the utilisation of antithrombotic therapy in older patients with atrial fibrillation. Age and Ageing. 2008;38(2):156–62. DOI:10.1093/ageing/afn293
5. Induruwa I, Evans NR, Aziz A, Reddy S, Khadjooi K, Romero- Ortuno R. Clinical frailty is independently associated with non-pre- scription of anticoagulants in older patients with atrial fibrillation: Frailty in atrial fibrillation. Geriatrics & Gerontology International. 2017;17(11):2178–83. DOI:10.1111/ggi.13058
6. Lefebvre M-CD, St-Onge M, Glazer-Cavanagh M, Bell L, Kha Nguyen JN, Viet-Quoc Nguyen P et al. The Effect of Bleeding Risk and Frailty Status on Anticoagulation Patterns in Octoge- narians with Atrial Fibrillation: The FRAIL-AF Study. Canadian Journal of Cardiology. 2016;32(2):169–76. DOI:10.1016/j.cjca.2015.05.012
7. Mant J, Hobbs FDR, Fletcher K, Roalfe A, Fitzmaurice D, Lip GYH et al. Warfarin versus aspirin for stroke prevention in an elderly com- munity population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet (London, England). 2007;370(9586):493– 503. DOI:10.1016/S0140-6736(07)61233-1
8. Kim HM, Choi E-K, Park CS, Cha M-J, Lee S-Y, Kwon J-M et al. Effectiveness and safety of non-vitamin K antagonist oral antico- agulants in octogenarian patients with non-valvular atrial fibrilla- tion. PLOS ONE. 2019;14(3):e0211766. DOI:10.1371/journal.pone.0211766
9. Chao T-F, Liu C-J, Lin Y-J, Chang S-L, Lo L-W, Hu Y-F et al. Oral Anticoagulation in Very Elderly Patients with Atrial Fibrillation: A Nationwide Cohort Study. Circulation. 2018;138(1):37–47. DOI:10.1161/CIRCULATIONAHA.117.031658
10. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New England Journal of Medicine. 2011;365(10):883–91. DOI:10.1056/NEJMoa1009638
11. Явелов И.С. Практические особенности использования ривароксабана для профилактики кардиоэмболических осложнений при неклапанной фибрилляции предсердий. Трудный пациент. 2014;12(10):16-23
12. Patel MR, Hellkamp AS, Lokhnygina Y, Piccini JP, Zhang Z, Mohan- ty S et al. Outcomes of Discontinuing Rivaroxaban Compared with Warfarin in Patients with Nonvalvular Atrial Fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). Journal of the American College of Cardiology. 2013;61(6):651–8. DOI:10.1016/j.jacc.2012.09.057
13. Halperin JL, Hankey GJ, Wojdyla DM, Piccini JP, Lokhnygina Y, Patel MR et al. Efficacy and Safety of Rivaroxaban Compared with Warfarin Among Elderly Patients with Nonvalvular Atrial Fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Preven- tion of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Circulation. 2014;130(2):138–46. DOI:10.1161/CIRCULA-TIONAHA.113.005008
14. Fox KAA, Piccini JP, Wojdyla D, Becker RC, Halperin JL, Nessel CC et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibril- lation and moderate renal impairment. European Heart Journal. 2011;32(19):2387–94. DOI:10.1093/eurheartj/ehr342
15. Lindner SM, Fordyce CB, Hellkamp AS, Lokhnygina Y, Pic- cini JP, Breithardt G et al. Treatment Consistency Across Lev- els of Baseline Renal Function With Rivaroxaban or Warfarin: A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Preven- tion of Stroke and Embolism Trial in Atrial Fibrillation) Analysis. Circulation. 2017;135(10):1001–3. DOI:10.1161/CIRCULA-TIONAHA.116.024666
16. Yao X, Tangri N, Gersh BJ, Sangaralingham LR, Shah ND, Nath KA et al. Renal Outcomes in Anticoagulated Patients with Atrial Fibrillation. Journal of the American College of Cardiology. 2017;70(21):2621–32. DOI:10.1016/j.jacc.2017.09.1087
17. De Torbal A, Boersma E, Kors JA, van Herpen G, Deckers JW, van der Kuip DAM et al. Incidence of recognized and unrecog- nized myocardial infarction in men and women aged 55 and older: the Rotterdam Study. European Heart Journal. 2006;27(6):729–36. DOI:10.1093/eurheartj/ehi707
18. Barkas F, Liberopoulos E, Klouras E, Liontos A, Liamis G, Elisaf M. Correlation between the CHADS2, CHA2DS2-VASC scores and the incidence of cardiovascular disease in individuals with- out atrial fibrilation and their comparison with hellenic score and ASCVD risk. Atherosclerosis. 2017;263:e173. DOI:10.1016/j.atherosclerosis.2017.06.553
19. Modi R, Patted SV, Halkati PC, Porwal S, Ambar S, Mr P et al. CHA2DS2-VASc-HSF score – New predictor of severity of coro- nary artery disease in 2976 patients. International Journal of Cardi- ology. 2017;228:1002–6. DOI:10.1016/j.ijcard.2016.10.093
20. Zhou X, Cao K, Kou S, Qu S, Li H, Yu Y et al. Usefulness of CHADS2 score for prognostic stratification of patients with coronary artery disease: A systematic review and meta-analysis of cohort stud- ies. International Journal of Cardiology. 2017;228:906–11. DOI:10.1016/j.ijcard.2016.11.114
21. Gómez-Outes A, Lagunar-Ruíz J, Terleira-Fernández A-I, Calvo- Rojas G, Suárez-Gea ML, Vargas-Castrillón E. Causes of Death in Anticoagulated Patients with Atrial Fibrillation. Journal of the American College of Cardiology. 2016;68(23):2508–21. DOI:10.1016/j.jacc.2016.09.944
22. Mahaffey KW, Stevens SR, White HD, Nessel CC, Goodman SG, Piccini JP et al. Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibi- tion: results from the ROCKET AF trial. European Heart Journal. 2014;35(4):233–41. DOI:10.1093/eurheartj/eht428
23. Mak K-H. Coronary and mortality risk of novel oral antithrom- botic agents: a meta-analysis of large randomised trials. BMJ Open. 2012;2(5):e001592. DOI:10.1136/bmjopen-2012-001592
24. Loke YK, Pradhan S, Yeong JK, Kwok CS. Comparative coronary risks of apixaban, rivaroxaban and dabigatran: a meta-analysis and adjusted indirect comparison. British Journal of Clinical Pharma- cology. 2014;78(4):707–17. DOI:10.1111/bcp.12376
25. Chatterjee S, Sharma A, Uchino K, Biondi-Zoccai G, Lichstein E, Mukherjee D. Rivaroxaban and risk of myocardial infarction: insights from a meta-analysis and trial sequential analysis of ran- domized clinical trials. Coronary Artery Disease. 2013;24(8):628– 35. DOI:10.1097/MCA.0000000000000031
26. Tornyos A, Kehl D, D’Ascenzo F, Komócsi A. Risk of Myocardial Infarction in Patients with Long-Term Non-Vitamin K Antagonist Oral Anticoagulant Treatment. Progress in Cardiovascular Diseases. 2016;58(5):483–94. DOI:10.1016/j.pcad.2015.12.001
27. Piccini JP, Hellkamp AS, Washam JB, Becker RC, Breithardt G, Berkowitz SD et al. Polypharmacy and the Efficacy and Safety of Riva- roxaban Versus Warfarin in the Prevention of Stroke in Patients with Nonvalvular Atrial Fibrillation. Circulation. 2016;133(4):352–60. DOI:10.1161/CIRCULATIONAHA.115.018544
28. Martinez BK, Sood NA, Bunz TJ, Coleman CI. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfa- rin in Frail Patients with Nonvalvular Atrial Fibrillation. Journal of the American Heart Association. 2018;7(8):e008643. DOI:10.1161/JAHA.118.008643
29. Walsh CA, Cahir C, Tecklenborg S, Byrne C, Culbertson MA, Bennett KE. The association between medication non‐adherence and adverse health outcomes in ageing populations: A systematic review and meta‐analysis. British Journal of Clinical Pharmacology. 2019;85(11):2464–78. DOI:10.1111/bcp.14075
30. Yamashiro K, Kurita N, Tanaka R, Ueno Y, Miyamoto N, Hira K et al. Adequate Adherence to Direct Oral Anticoagulant is Asso- ciated with Reduced Ischemic Stroke Severity in Patients with Atrial Fibrillation. Journal of Stroke and Cerebrovascular Dis- eases. 2019;28(6):1773–80. DOI:10.1016/j.jstrokecerebrovas-dis.2018.09.019
31. Качковский М.А., Краснослободская О.В. Приверженность медикаментозной терапии больных с фибрилляцией предсердий. Вестник Российского университета дружбы народов. Серия: Медицина. 2010;4:229-33
32. Chen LY, Norby FL, Gottesman RF, Mosley TH, Soliman EZ, Agarwal SK et al. Association of Atrial Fibrillation with Cognitive Decline and Dementia Over 20 Years: The ARIC‐NCS (Atheroscle- rosis Risk in Communities Neurocognitive Study). Journal of the American Heart Association. 2018;7(6):e007301. DOI:10.1161/JAHA.117.007301
33. Cheng W, Liu W, Li B, Li D. Relationship of Anticoagulant Therapy with Cognitive Impairment Among Patients with Atrial Fibril- lation: A Meta‐Analysis and Systematic Review. Journal of Car- diovascular Pharmacology. 2018;71(6):380–7. DOI:10.1097/FJC.0000000000000575
34. Diener H-C, Hart RG, Koudstaal PJ, Lane DA, Lip GYH. Atrial Fibrillation and Cognitive Function. Journal of the American College of Cardiology. 2019;73(5):612–9. DOI:10.1016/j.jacc.2018.10.077
35. Andrade JG, Krahn AD, Skanes AC, Purdham D, Ciaccia A, Con- nors S. Values and Preferences of Physicians and Patients with Nonvalvular Atrial Fibrillation Who Receive Oral Anticoagulation Therapy for Stroke Prevention. Canadian Journal of Cardiology. 2016;32(6):747–53. DOI:10.1016/j.cjca.2015.09.023
36. Suzuki T, Shiga T, Omori H, Tatsumi F, Nishimura K, Hagi- wara N. Adherence to medication and characteristics of Japanese patients with non-valvular atrial fibrillation. Journal of Cardiology. 2017;70(3):238–43. DOI:10.1016/j.jjcc.2016.11.009
37. Weeda ER, Coleman CI, McHorney CA, Crivera C, Schein JR, Sobi- eraj DM. Impact of once- or twice-daily dosing frequency on adher- ence to chronic cardiovascular disease medications: A meta-regres- sion analysis. International Journal of Cardiology. 2016;216:104–9. DOI:10.1016/j.ijcard.2016.04.082
38. McHorney CA, Ashton V, Laliberté F, Germain G, Wynant W, Crivera C et al. Adherence to Rivaroxaban Compared with Other Oral Anticoagulant Agents Among Patients with Nonvalvular Atrial Fibrillation. Journal of Managed Care & Specialty Pharmacy. 2017;23(9):980–8. DOI:10.18553/jmcp.2017.23.9.980
39. Государственный реестр лекарственных средств. Инструкция по применению лекарст- венного препарата для медицинского применения Ксарелто® (ЛП-001457). Доступно на: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=00d65fd8-a24c-450c-903c-58bb53e5e69d&t=